Please assess the completion status of the following clinical trial:

Trial Title: Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~- For protocol 1: i. Aged between 18-40 or 65-75 years ii. A body mass index (BMI) \>18 and \<28 kg/m2~- For Protocol 2: i. Age 65-75 years ii. A body mass index (BMI) \>18 and \<28 kg/m2~Exclusion Criteria:~* For protocol 1:~  i. A BMI \< 18 or \> 28 kg·m2 ii. Active cardiovascular disease: uncontrolled hypertension (BP \> 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt or recent cardiac event iii. Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial) iv. Respiratory disease including pulmonary hypertension, chronic obstructive pulmonary disease (COPD), asthma or an forced expiratory volume in 1 minute (FEV1) less than 1.5 litre.~  v. Metabolic disease: hyper and hypo-parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes vi. Active inflammatory bowel or renal disease vii. Malignancy viii. Recent steroid treatment (within 6 month), or hormone replacement therapy ix. Clotting dysfunction x. Musculoskeletal or neurological disorders xi. Family history of early (\<55y) death from cardiovascular disease~* For protocol 2:~Same as protocol 1 in addition to:~i. Overt muscle wasting i.e. muscle mass is more than 1 standard deviation below normal muscle or fat-free mass for age.~ii. Taking beta-adrenergic blocking agents or non-steroidal anti-inflammatory drugs iii. Known sensitivity to SONOVUE or any other drug used in the study. iv. Subject deemed unsuitable for femoral cannulation at screening visit.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Post absorptive insulin without GLP-1 (Type: EXPERIMENTAL): Subjects with receive post absorptive insulin concentrations while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.~The intervention in this group is Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition.
- Postabsorptive insulin with GLP-1 (Type: EXPERIMENTAL): Subjects will receive post absorptive insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve post absorptive insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L .
- Postprandial insulin without GLP-1 (Type: EXPERIMENTAL): Subjects will receive postprandial insulin concentrations without GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours.~The intervention in this group is Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L . This will form base line measurement for the next arm which will receive GLP-1 in addition
- Postprandial insulin with GLP-1 (Type: EXPERIMENTAL): Subjects with receive postprandial insulin concentrations with GLP-1 while measures of muscle metabolism and microvascular blood flow are taken through the acute study hours. This arm will cross over with the previous arm.~The intervention in this group is in the form of GLP-1, Insulin Actrapid to achieve postprandial insulin levels and glucose infusion to achieve postprandial glucose levels of 7.0-7.5 mmol/L .
- Oral amino acids-Young (Type: EXPERIMENTAL): Gut hormones will be measured post oral drink containing 15 g of amino acids in young persons. This will cross over with the following 2 arms.~The intervention here is: 15g of mixed essential amino acid drink.
- Intravenous (IV) amino acids- Young (Type: EXPERIMENTAL): Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids in young persons.~The intervention in this group: Intravenous amino acids delivering iso-equivalent amount of 15g mixed essential amino acids
- IV amino acids, GLP-1, GIP -Young (Type: EXPERIMENTAL): Gut hormones will be measured after intravenous amino acid infusion delivering iso equivalent amount of amino acids, GLP-1, GIP in young persons.~The intervention in this group: Intravenous amino acids iso-equivalent to oral 15 g mixed essential amino acids, GLP-1 infusion and GIP infusion
- Oral amino acids- Older (Type: EXPERIMENTAL): Gut hormones will be measured post oral drink containing 15 g of mixed essential amino acids in older persons.~The intervention in this arm: 15 gram of oral mixed essential amino acid drink

Based on this trial design, predict the completion outcome and termination type (if applicable).